Clinical Trials
23 trialsNCT05363319 2026-05-13
CEMI-LUNG
Regeneron Pharmaceuticals
Recruiting
NCT07416474 2026-04-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT05614102 2026-03-31
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT06465329 2026-02-12
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT04486833 2026-01-21
Acclaim-1
Genprex, Inc.
Phase 1/2 Recruiting
NCT07141563 2026-01-07
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
Bristol-Myers Squibb
Completed
NCT06216301 2025-12-17
LUNAR-2
NovoCure Ltd.
Phase 3 Recruiting
NCT07170995 2025-11-18
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07215962 2025-10-14
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb
Active not recruiting
NCT04906993 2025-09-09
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT07063329 2025-07-25
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
Avistone Pharmaceutical(Ningbo)Co., LTD.
Phase 1/2 Not yet recruiting
NCT05607550 2025-06-22
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma, Inc.
Phase 3 Active not recruiting
NCT05338970 2025-01-31
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04428333 2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3 Terminated
NCT06169956 2024-04-18
NENI
Bristol-Myers Squibb
Recruiting
NCT05862194 2023-08-22
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Yuhan Corporation
Completed
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT05416775 2022-08-19
Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT03322566 2022-01-24
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Incyte Corporation
Phase 2 Completed
NCT00404703 2016-08-24
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00451906 2016-05-24
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Hoffmann-La Roche
Phase 4 Completed
NCT00371566 2010-04-06
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed